Pharmacogenomics, Pharmacoproteomics, and Pharmacometabolomics and Personalized Medicine: An Overview
作者： Nalini Raghavachari , Marjan Gucek
DOI: 10.1007/978-81-322-1184-6_1
关键词:
摘要: The mapping of the human genome has been an important milestone in understanding interindividual differences genetic predisposition to diseases and individuals’ responsiveness drugs. These factors have now begun revolutionize clinical landscape with new therapeutic strategies defined as “personalized medicine.” Personalized medicine is believed transform traditional “one size fits all” model by applying individual gene-based information better manage a patient’s disease or toward tailor for prevention treatment diseases. In this context, recent explosion omics tools technologies generate valuable pharmacogenomic, proteomic, metabolic patients which would serve potential accelerating development personalized medicine. ability change overall from diagnosis prevention. success therapy future will depend on scientific advances pharmacogenomics, proteomics, metabolics systems biology approach complex This chapter discusses basic concepts advancements fields pharmacoproteomics, pharmacometabolomics their applications
springer.com
sci-hub.st 参考文章(88)
Alexander Korman, Amy Oh, Alexander Raskind, David Banks, Statistical Methods in Metabolomics Methods of Molecular Biology. ,vol. 856, pp. 381- 413 ,(2012) , 10.1007/978-1-61779-585-5_16
S Panareo, E Degli Uberti, R Rossi, S Fabbri, G De Paola, G C Candini, L Feggi, A practical method for the estimation of therapeutic activity in the treatment of Graves' hyperthyroidism The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology. ,vol. 55, pp. 576- 585 ,(2011)
Lara M Mangravite, Russell A Wilke, Ronald M Krauss, Jiong Zhang, Pharmacogenomics of statin response. Current Opinion in Molecular Therapeutics. ,vol. 10, pp. 555- 561 ,(2008)
Jost Klawitter, Manuel Haschke, Christine Kahle, Colleen Dingmann, Jelena Klawitter, Dieter Leibfritz, Uwe Christians, Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose British Journal of Clinical Pharmacology. ,vol. 70, pp. 241- 251 ,(2010) , 10.1111/J.1365-2125.2010.03689.X
Darwin Lewis Conwell, Vivek Kadiyala, Joao A Paulo, Peter Alan Banks, Hanno Steen, Mass spectrometry-based proteomics for translational research: a technical overview. Yale Journal of Biology and Medicine. ,vol. 85, pp. 59- 73 ,(2012)
T. Andrew Clayton, John C. Lindon, Olivier Cloarec, Henrik Antti, Claude Charuel, Gilles Hanton, Jean-Pierre Provost, Jean-Loïc Le Net, David Baker, Rosalind J. Walley, Jeremy R. Everett, Jeremy K. Nicholson, Pharmaco-metabonomic phenotyping and personalized drug treatment Nature. ,vol. 440, pp. 1073- 1077 ,(2006) , 10.1038/NATURE04648
Jacob N. Beverage, Tristan M. Sissung, Amy M. Sion, Romano Danesi, William D. Figg, CYP2D6 polymorphisms and the impact on tamoxifen therapy Journal of Pharmaceutical Sciences. ,vol. 96, pp. 2224- 2231 ,(2007) , 10.1002/JPS.20892
Simone Mocellin, Jeff Shrager, Richard Scolyer, Sandro Pasquali, Daunia Verdi, Francesco M. Marincola, Marta Briarava, Randy Gobbel, Carlo Rossi, Donato Nitti, Targeted Therapy Database (TTD): a model to match patient's molecular profile with current knowledge on cancer biology PLOS ONE. ,vol. 5, ,(2010) , 10.1371/JOURNAL.PONE.0011965
Alfred C. O. Vertegaal, Uncovering Ubiquitin and Ubiquitin-like Signaling Networks Chemical Reviews. ,vol. 111, pp. 7923- 7940 ,(2011) , 10.1021/CR200187E
Hyun Joo An, John W Froehlich, Carlito B Lebrilla, Determination of glycosylation sites and site-specific heterogeneity in glycoproteins. Current Opinion in Chemical Biology. ,vol. 13, pp. 421- 426 ,(2009) , 10.1016/J.CBPA.2009.07.022